Literature DB >> 7285267

Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R.

O I Kellina.   

Abstract

The present epidemiological situation of the three nosoforms of leismaniasis (i.e. anthroponotic cutaneous leishmaniasis, zoonotic cutaneous leishmainiasis and visceral leishmaniasis) in the U.S.S.R. is exposed. The current lines in inveestigation of their epidemiology are then presented, with special reference to the methods used and the results obtained for their control.

Entities:  

Mesh：

Year:  1981        PMID： 7285267

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot Filiales


  11 in total

1.  Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Authors:  Salvador Iborra; Javier Carrión; Charles Anderson; Carlos Alonso; David Sacks; Manuel Soto
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.

Authors:  Khaled S Tabbara; Nathan C Peters; Farhat Afrin; Susana Mendez; Sylvie Bertholet; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 4.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

6.  Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

Authors:  Nathan C Peters; Sylvie Bertholet; Phillip G Lawyer; Melanie Charmoy; Audrey Romano; Flavia L Ribeiro-Gomes; Lisa W Stamper; David L Sacks
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

Review 7.  Immune regulation during chronic visceral leishmaniasis.

Authors:  Rebecca J Faleiro; Rajiv Kumar; Louise M Hafner; Christian R Engwerda
Journal:  PLoS Negl Trop Dis       Date:  2014-07-10

Review 8.  Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against Leishmania.

Authors:  Negar Seyed; Nathan C Peters; Sima Rafati
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

9.  Vector transmission of leishmania abrogates vaccine-induced protective immunity.

Authors:  Nathan C Peters; Nicola Kimblin; Nagila Secundino; Shaden Kamhawi; Phillip Lawyer; David L Sacks
Journal:  PLoS Pathog       Date:  2009-06-19       Impact factor: 6.823

10.  Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.

Authors:  Kumar Avishek; Himanshu Kaushal; Sreenivas Gannavaram; Ranadhir Dey; Angamuthu Selvapandiyan; V Ramesh; Narender Singh Negi; Uma S Dubey; Hira L Nakhasi; Poonam Salotra
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.